The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

被引：487

作者：

Yuan, Min ^{[1
,2
]}

Huang, Li-Li ^{[1
,2
]}

Chen, Jian-Hua ^{[1
,3
]}

Wu, Jie ^{[3
,4
]}

Xu, Qing ^{[1
,2
]}

机构：

[1] Tongji Univ, Dermatol Hosp, Dept Oncol, Sch Med, Shanghai 200443, Peoples R China

[2] Tongji Univ, Shanghai Peoples Hosp 10, Dept Oncol, Sch Med, Shanghai 200072, Peoples R China

[3] Univ Oklahoma, Hlth Sci Ctr, Peggy & Charles Stephenson Canc Ctr, Oklahoma City, OK 73104 USA

[4] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA

来源：

SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2019年 / 4卷 / 1期

基金：

中国国家自然科学基金;

关键词：

EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE INHIBITORS; ANTI-HER3; MONOCLONAL-ANTIBODY; NIVOLUMAB PLUS IPILIMUMAB; RECEPTOR GENE-MUTATIONS; RANDOMIZED PHASE-III; OPEN-LABEL; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; EGFR MUTATIONS;

D O I：

10.1038/s41392-019-0099-9

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Lung cancer is one of the most common cancer in the world. In 2018, there were over 2 million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer. Targeted therapy has emerged as an important mean of the disease management for patients with non-small-cell lung cancer (NSCLC). Herein, we review and analyze recent literature, discuss the targeting pathways and ongoing clinical trials in lung cancer. Chemotherapy is no longer the best available treatment for all patients. Therapeutic decisions should be guided by an understanding of the molecular features of patient's tumor tissues. The future gains will likely emerge from finding optimal ways of combining targeted therapy, immunotherapy, and chemotherapy.

引用

页数：14

共 50 条

[21] Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
Stinchcombe, Thomas E.
Ramalingam, Suresh S.
LANCET ONCOLOGY, 2010, 11 (06): : 500 - 501
[22] Emerging therapies in non-small-cell lung cancer
Khuri, FR
Herbst, RS
Fossella, FV
ANNALS OF ONCOLOGY, 2001, 12 (06) : 739 - 744
[23] Emerging drugs for non-small-cell lung cancer
Felip, Enriqueta
Santarpia, Mariacarmela
Rosell, Rafael
EXPERT OPINION ON EMERGING DRUGS, 2007, 12 (03) : 449 - 460
[24] Correction: Targeted therapy in non-small-cell lung cancer—is it becoming a reality?
F. Janku
D. J. Stewart
R. Kurzrock
Nature Reviews Clinical Oncology, 2011, 8 : 384 - 384
[25] Targeted therapy in non-small-cell lung cancer-is it becoming a reality?
Janku, Filip
Stewart, David J.
Kurzrock, Razelle
NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (07) : 401 - 414
[26] Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer
Giovannetti, Elisa
Erdem, Lale
Olcay, Efnan
Leon, Leticia G.
Peters, Godefridus J.
FRONTIERS IN BIOSCIENCE-LANDMARK, 2011, 16 : 116 - 130
[27] Is there a role for maintenance therapy in non-small-cell lung cancer? An emerging issue
Petrelli, Fausto
Ghilardi, Mara
Cremonesi, Marco
Cabiddu, Mary
Barni, Sandro
EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (10) : 1455 - 1465
[28] Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer
Pabani, A.
Butts, C. A.
CURRENT ONCOLOGY, 2018, 25 : S94 - S102
[29] Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
Tiseo, M.
Bartolotti, M.
Gelsomino, F.
Bordi, P.
DRUG DESIGN DEVELOPMENT AND THERAPY, 2010, 4 : 81 - 98
[30] Integrating new targeted agents into the treatment of non-small-cell lung cancer
Thatcher, Nick
LUNG CANCER, 2006, 54 : S25 - S31

← 1 2 3 4 5 →